Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 4-Year Follow-up from the Phase 2 ZUMA-5 Trial

Neelapu, S. S., Chavez, J. C., Sehgal, A. R., Epperla, N., Ulrickson, M. L., Bachy, E., Munshi, P. N., Casulo, C., Maloney, D. G., de Vos, S., Reshef, R., Leslie, L. A., Oluwole, O. O., Yakoub-Agha, I., Khanal, R., Rosenblatt, J. D., Peng, W., Lui, C., Wulff, J., … Jacobson, C. A. (2023). Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 4-Year Follow-up from the Phase 2 ZUMA-5 Trial. Blood, 142(Supplement 1), 4868–4868. https://doi.org/10.1182/blood-2023-174914
Authors:
Sattva S. Neelapu
Julio C. Chávez
Alison R. Sehgal
Narendranath Epperla
Matthew L. Ulrickson
Emmanuel Bachy
Pashna N. Munshi
Carla Casulo
David G. Maloney
Sven de Vos
Ran Reshef
Lori A. Leslie
Olalekan O. Oluwole
Ibrahim Yakoub‐Agha
Rashmi Khanal
Joseph D. Rosenblatt
Weixin Peng
Christine Lui
Jacob Wulff
Rhine R. Shen
Soumya Poddar
Andrew Lee
Harry Miao
Olga Nikolajeva
Caron A. Jacobson
Affiliated Authors:
Ran Reshef
Publication Type:
Article
Unique ID:
10.1182/blood-2023-174914
Journal:
Publication Date:
Data Source:
OpenAlex

Record Created: